| NCT ID | NCT07102615 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Prisma Health-Upstate |
| Condition | Retained Products of Conception |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 50 participants in total. It began in 2025-10-30 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus. The main goal of the study is : • To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC. Participants will: • would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.
Eligibility Criteria
Inclusion Criteria: * Women * Aged 18-51 * Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion Exclusion Criteria: * Hemodynamic instability * Active hemorrhage- soaking pad/hour * Allergy to vasopressin * Concern for intrauterine arteriovenous malformation * Inability to consent
Contact & Investigator
Paul Miller, MD
STUDY DIRECTOR
Prisma Health
Frequently Asked Questions
Who can join the NCT07102615 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 51 Years, studying Retained Products of Conception. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07102615 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07102615 currently recruiting?
Yes, NCT07102615 is actively recruiting participants. Contact the research team at patti.parker@prismahealth.org for enrollment information.
Where is the NCT07102615 trial being conducted?
This trial is being conducted at Greenville, United States.
Who is sponsoring the NCT07102615 clinical trial?
NCT07102615 is sponsored by Prisma Health-Upstate. The principal investigator is Paul Miller, MD at Prisma Health. The trial plans to enroll 50 participants.